Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Wiad Lek ; 52(9-10): 462-9, 1999.
Artigo em Polonês | MEDLINE | ID: mdl-10628270

RESUMO

During recent years, gastric ECL cells have attracted much attention, mainly due to the fact that mice and rats were found to develop gastric carcinoids following lifelong treatment with blockers of acid secretion. We present the structure and functions of ECL cells and their influence on physiology and pathology of stomach and duodenum. We describe interactions of enzymes and hormones in histamine-stimulated gastric output.


Assuntos
Antiulcerosos/efeitos adversos , Neoplasias Duodenais/induzido quimicamente , Neoplasias Duodenais/patologia , Úlcera Duodenal/tratamento farmacológico , Celulas Tipo Enterocromafim/patologia , Hormônios Pancreáticos/efeitos adversos , Neoplasias Gástricas/induzido quimicamente , Neoplasias Gástricas/patologia , Úlcera Gástrica/tratamento farmacológico , Animais , Cromogranina A , Gastrinas/metabolismo , Histamina/metabolismo , Camundongos , Ratos
2.
Fundam Clin Pharmacol ; 6(8-9): 359-66, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1292967

RESUMO

One hundred and eleven pre-pubertal children (70 boys, 41 girls, aged 2.5 to 14.3 years) with growth failure (height 2 SD below the mean for chronological age (CA) and height velocity (HV) below the 10th percentile for bone age) due to idiopathic growth hormone deficiency (peak plasma GH < 20 mUI/1 to two standard provocative tests) were treated with GHRH 1-44 NH2. Patient stratification in two classes was performed according to body weight; in each class, patients were randomly allocated to one of seven GHRH doses, from 30 to 300 micrograms/day. GHRH was injected subcutaneously, every evening, for six months in a double-blind fashion. No relationship was found between the absolute or incremental HV during treatment and the dose (range from 1.3-23.1 micrograms/kg/day) of GHRH. However, HV (cm/year) increased from 3.8 +/- 0.1 (mean +/- SEM) before treatment to 6 +/- 0.2 during six months treatment and 47 patients (42%) increased their HV up to at least the mean normal HV for bone age (catch-up growth). Low titer antibodies to GHRH were found in 19 patients (17.1%) at six months; no adverse effect was observed. Our results suggest that patients showing catch-up growth were older, had a height closer to the mean for chronological age and a slower pre-treatment height velocity. Failure to demonstrate a relationship between GHRH dose and changes in growth velocity might be explained by the combination of a placebo effect, insufficient frequency of GHRH administration and heterogeneity of the population.


Assuntos
Estatura/efeitos dos fármacos , Hormônio Liberador de Hormônio do Crescimento/análogos & derivados , Hormônio do Crescimento/deficiência , Hormônios Pancreáticos/uso terapêutico , Fragmentos de Peptídeos/uso terapêutico , Adolescente , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Hormônio Liberador de Hormônio do Crescimento/administração & dosagem , Hormônio Liberador de Hormônio do Crescimento/efeitos adversos , Hormônio Liberador de Hormônio do Crescimento/uso terapêutico , Humanos , Masculino , Hormônios Pancreáticos/administração & dosagem , Hormônios Pancreáticos/efeitos adversos , Cooperação do Paciente , Fragmentos de Peptídeos/administração & dosagem , Fragmentos de Peptídeos/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...